Plasma xanthine oxidoreductase activity in Japanese patients with type 2 diabetes across hospitalized treatment
暂无分享,去创建一个
I. Shimomura | S. Fukuda | H. Nishizawa | N. Maeda | S. Kita | M. Takahara | N. Katakami | Y. Fujishima | T. Murase | Takashi Nakamura | Yusuke Kawachi | Seigo Akari | H. Nagao | Naohiro Taya | Kazuo Omori | A. Miyake | Shunbun Kita
[1] F. Hu,et al. Visceral and ectopic fat, atherosclerosis, and cardiometabolic disease: a position statement. , 2019, The lancet. Diabetes & endocrinology.
[2] K. Shimamoto,et al. Annual change in plasma xanthine oxidoreductase activity is associated with changes in liver enzymes and body weight. , 2019, Endocrine journal.
[3] J. Borén,et al. Crosstalk between nonalcoholic fatty liver disease and cardiometabolic syndrome , 2018, Obesity reviews : an official journal of the International Association for the Study of Obesity.
[4] G. Homanics,et al. Hepatocyte-Specific Ablation or Whole-Body Inhibition of Xanthine Oxidoreductase in Mice Corrects Obesity-Induced Systemic Hyperuricemia Without Improving Metabolic Abnormalities , 2019, Diabetes.
[5] B. Zinman,et al. Empagliflozin is associated with improvements in liver enzymes potentially consistent with reductions in liver fat: results from randomised trials including the EMPA-REG OUTCOME® trial , 2018, Diabetologia.
[6] S. Okamoto,et al. Activity of xanthine oxidase in plasma correlates with indices of insulin resistance and liver dysfunction in patients with type 2 diabetes mellitus and metabolic syndrome: A pilot exploratory study , 2018, Journal of diabetes investigation.
[7] K. Shimamoto,et al. Plasma Xanthine Oxidoreductase Activity as a Novel Biomarker of Metabolic Disorders in a General Population. , 2018, Circulation journal : official journal of the Japanese Circulation Society.
[8] E. Fukusaki,et al. Hypoxanthine Secretion from Human Adipose Tissue and its Increase in Hypoxia , 2018, Obesity.
[9] Dongli Tian,et al. Effects of sodium‐glucose co‐transporter 2 (SGLT2) inhibitors on serum uric acid level: A meta‐analysis of randomized controlled trials , 2018, Diabetes, obesity & metabolism.
[10] Y. Moriwaki,et al. Xanthine oxidoreductase activity is correlated with insulin resistance and subclinical inflammation in young humans. , 2017, Metabolism: clinical and experimental.
[11] Herbert Tilg,et al. Non-alcoholic fatty liver disease and its relationship with cardiovascular disease and other extrahepatic diseases , 2017, Gut.
[12] M. Oka,et al. A highly sensitive assay of human plasma xanthine oxidoreductase activity using stable isotope-labeled xanthine and LC/TQMS. , 2016, Journal of chromatography. B, Analytical technologies in the biomedical and life sciences.
[13] Yingying Ding,et al. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: A systematic review and meta-analysis , 2016, Scientific Reports.
[14] E. Kelley. A new paradigm for XOR-catalyzed reactive species generation in the endothelium , 2015, Pharmacological reports : PR.
[15] C. Byrne,et al. NAFLD: a multisystem disease. , 2015, Journal of hepatology.
[16] L. Polito,et al. Xanthine oxidoreductase in atherosclerosis pathogenesis: not only oxidative stress. , 2014, Atherosclerosis.
[17] H. Yki-Järvinen. Non-alcoholic fatty liver disease as a cause and a consequence of metabolic syndrome. , 2014, The lancet. Diabetes & endocrinology.
[18] L. Polito,et al. Pathophysiology of circulating xanthine oxidoreductase: new emerging roles for a multi-tasking enzyme. , 2014, Biochimica et biophysica acta.
[19] M. Al-mallah,et al. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care? , 2013, Atherosclerosis.
[20] T. Funahashi,et al. Uric Acid Secretion from Adipose Tissue and Its Increase in Obesity* , 2013, The Journal of Biological Chemistry.
[21] L. Dimeglio,et al. Type 1 Diabetes , 2019, Epidemiology of Diabetes.
[22] H. Kaneto,et al. Serum endogenous secretory RAGE level is an independent risk factor for the progression of carotid atherosclerosis in type 1 diabetes. , 2009, Atherosclerosis.
[23] 大坪 俊夫. Xanthine oxidoreductase 遺伝子欠損マウスの解析 , 2008 .
[24] J. Hare,et al. Xanthine oxidoreductase and cardiovascular disease: molecular mechanisms and pathophysiological implications , 2004, The Journal of physiology.
[25] H. J. Frank. The Authors , 2002, Gov. Inf. Q..
[26] A. Meneshian,et al. The Physiology of Endothelial Xanthine Oxidase: From Urate Catabolism to Reperfusion Injury to Inflammatory Signal Transduction , 2002, Microcirculation.
[27] S. Marklund,et al. Binding of Xanthine Oxidase to Vascular Endothelium , 1999, The Journal of Biological Chemistry.
[28] P. Hassoun,et al. Upregulation of xanthine oxidase by lipopolysaccharide, interleukin-1, and hypoxia. Role in acute lung injury. , 1998, American journal of respiratory and critical care medicine.
[29] M. Calzi,et al. Tissue- and cell-specific expression of mouse xanthine oxidoreductase gene in vivo: regulation by bacterial lipopolysaccharide. , 1995, The Biochemical journal.
[30] K. Hirano,et al. Binding of human xanthine oxidase to sulphated glycosaminoglycans on the endothelial-cell surface. , 1993, The Biochemical journal.
[31] J. Gollan,et al. Enhanced activity of the free radical producing enzyme xanthine oxidase in hypoxic rat liver. Regulation and pathophysiologic significance. , 1991, The Journal of clinical investigation.
[32] H. P. Jones,et al. Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues. , 1987, The Journal of clinical investigation.
[33] H. Tomita,et al. Establishment of the Process in Blood Sampling and Sample Handling as a Biomarker of Hypoxia-Inducible Diseases; Plasma Hypoxanthine and Xanthine Measurement , 2018 .
[34] J. Ampuero,et al. Association of NAFLD with subclinical atherosclerosis and coronary-artery disease: meta-analysis. , 2015, Revista espanola de enfermedades digestivas : organo oficial de la Sociedad Espanola de Patologia Digestiva.
[35] [Evidence-based practice guideline for the treatment of CKD]. , 2009, Nihon Jinzo Gakkai shi.
[36] S. Yamashita,et al. Studies on the impaired metabolism of uric acid in obese subjects: marked reduction of renal urate excretion and its improvement by a low-calorie diet. , 1986, International journal of obesity.